Decision Resources Group says that a survey of US payers found that 90 percent said they would pay a premium for a new treatment that does a significantly better job of reducing asthma exacerbations than Xolair (omalizumab).
The survey results are in a report titled “Asthma (Moderate to Severe): Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy?”
According to Decision Resources, the survey also found that pulmonologists noted a need for therapies that produce greater quality of life improvements, and the report states that “No emerging therapies are positively differentiated from the market leader, GlaxoSmithKline’s Advair/Seretide/Adoair, on this attribute, based on clinical data and according to the opinions of interviewed thought leaders.”
On the subject of less-frequent dosing, Analyst Eun-Jin Yang commented, “Even though less-frequent administration received the highest level of unmet need among delivery attributes, surveyed US and European pulmonologists assigned it only a low to moderate level of unmet need, respectively. This suggests that, at least for US pulmonologists, it may merely be an issue of convenience and not a major priority.”
Read the Decision Resources press release.
